Home » Stocks » VCYT

Veracyte, Inc. (VCYT)

Stock Price: $45.97 USD 0.66 (1.46%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
After-hours: $43.77 -2.20 (-4.79%) Apr 20, 5:25 PM
Market Cap 3.09B
Revenue (ttm) 117.48M
Net Income (ttm) -34.91M
Shares Out 53.24M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $45.97
Previous Close $45.31
Change ($) 0.66
Change (%) 1.46%
Day's Open 44.76
Day's Range 43.70 - 46.21
Day's Volume 775,075
52-Week Range 21.19 - 86.03

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

These under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.

Other stocks mentioned: CDNA, NTRA
2 weeks ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference

2 weeks ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Appoints Muna Bhanji to Its Board of Directors

4 weeks ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Completes Acquisition of Decipher Biosciences

1 month ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Commends New USPSTF Lung Cancer Screening Guidelines

1 month ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference

2 months ago - Business Wire

Veracyte (VCYT) delivered earnings and revenue surprises of -55.56% and 0.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Veracyte (NASDAQ:VCYT) were unchanged in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 6.67% over the past year to ($0.14), which mis...

2 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

2 months ago - Business Wire

Veracyte Inc (NASDAQ: VCYT) has priced an upsized underwritten public offering of around 7.4 million common shares at $74 per share, with gross proceeds of approximately $550 million. Earlier, the compa...

2 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock

2 months ago - Business Wire

Veracyte Inc (NASDAQ: VCYT) has commenced an underwritten public offering of $400 million in common stock. Underwriters have an option to purchase up to an additional $60 million shares.

2 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced that it has commenced an underwritten public offering of $400.0 million in shares of its commo...

2 months ago - Business Wire

Veracyte Inc (NASDAQ: VCYT) has agreed to acquire Decipher Biosciences, a precision oncology company focused on urologic cancers, further solidifying Veracyte's position in the genomic cancer diagnostic...

2 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., & SAN DIEGO, Calif.--(BUSINESS WIRE)--Veracyte To Acquire Decipher Biosciences

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference

3 months ago - Business Wire

Veracyte (VCYT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Veracyte (Nasdaq:VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in th...

Other stocks mentioned: BAYRY
3 months ago - Business Wire

Veracyte has been able to show a strong recovery after struggling through the COVID-19 headwinds of Q2. Now, the company is looking to fill the gap and surpass 2019's numbers. I take a look at the compa...

3 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte received ISO 13485:2016 certification for the company's in vitro diagnostics Quality Management System.

3 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New General Manager Structure to Advance Global Expansion

5 months ago - Business Wire

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Veracyte (VCYT) delivered earnings and revenue surprises of 55.56% and 25.24%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Third Quarter 2020 Financial Results

5 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Prosigna Breast Cancer Test Data Published in Journal of Clinical Oncology

5 months ago - Business Wire

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Publication of Manuscript Describing Scientific Rigor Behind Next-Generation Percepta Genomic Sequencing Classifier

5 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Two Presentations to Be Shared at CHEST Annual Meeting 2020

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Release Third Quarter 2020 Financial Results on November 2, 2020

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the Centers for Medicare and Medicaid Services (CMS) has approved new Advanced Diagnostic Laboratory Test...

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at Two Investor Conferences

7 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Promotion of Richard T.

7 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Initiates Study to Generate Consensus on Medical Utility of Multiple Breast Cancer Genomic Tests

7 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at Upcoming Investor Conferences

7 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.

7 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announces positive clinical utility data for Percepta classifier published online in CHEST

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.

8 months ago - Business Wire

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Veracyte (VCYT) delivered earnings and revenue surprises of 0.00% and 17.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

About VCYT

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 30, 2013
CEO
Bonnie Anderson
Employees
320
Stock Exchange
NASDAQ
Ticker Symbol
VCYT
Full Company Profile

Financial Performance

In 2020, Veracyte's revenue was $117.48 million, a decrease of -2.40% compared to the previous year's $120.37 million. Losses were -$34.91 million, 177.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Veracyte stock is "Buy." The 12-month stock price forecast is 84.83, which is an increase of 84.53% from the latest price.

Price Target
$84.83
(84.53% upside)
Analyst Consensus: Buy